The KLHL7 Knouckout A-549 Polyclonal Cells product provides a versatile CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung carcinoma cell line. This gene-edited pool carries heterogeneous disruptions in the KLHL7 gene, enabling loss-of-function studies without clonal selection. The polyclonal format preserves genetic complexity while ensuring robust KLHL7 deficiency across the population, making it suitable for pooled functional genomics and high-content screening applications. Researchers can exploit this model to interrogate KLHL7-dependent processes in a disease-relevant epithelial background.
The A-549 parental cell line was originally established from the lung carcinoma tissue of a 58-year-old Caucasian male and is widely employed as a model of alveolar epithelial type II cells. A-549 cells retain key features of lung adenocarcinoma, including active drug metabolism pathways and oncogenic signaling networks, rendering them a valuable system for cancer biology and pharmacology research. Their adherent epithelial morphology and well-characterized response to chemotherapeutic agents enable physiologically relevant investigations of gene function in lung cancer progression and drug resistance.
KLHL7 encodes a substrate adaptor of the Cullin-RING E3 ubiquitin ligase complex, where it interacts with CUL3 and RBX1 to mediate polyubiquitination of target proteins and their subsequent proteasomal degradation. Among its identified substrates are the Dishevelled segment polarity protein DVL2 and the glioma-associated oncogene transcription factor GLI2, both critical transducers of Hedgehog signaling. By promoting turnover of DVL2 and GLI2, KLHL7 functions as a negative regulator of the Hedgehog pathway, which further involves the receptor PTCH1 and the signal transducer SMO. This regulatory circuit links KLHL7 to the control of cell proliferation, cell cycle progression, and ciliogenesis. Upstream signals controlling KLHL7 activity remain poorly defined, highlighting the need for functional studies.
In A-549 lung carcinoma cells, KLHL7 disruption is expected to increase DVL2 and GLI2 protein stability, potentially activating Hedgehog target genes and altering cell proliferation. This aligns with reported tumor-suppressive roles of ubiquitin ligase adaptors in lung adenocarcinoma. The model thus offers a tool to study how aberrant Hedgehog signaling contributes to cancer phenotypes, and to investigate KLHL7??s impact on drug metabolism and resistance in an alveolar epithelial context.
The polyclonal KLHL7 knockout cells are suited for functional genomics screens, Hedgehog reporter assays, and quantitative analysis of ubiquitin-dependent degradation. Assay compatibility includes Western blotting, RT-qPCR, immunofluorescence, flow cytometry, proliferation and migration assays, and drug sensitivity testing with chemotherapeutics. Researchers can also perform co-immunoprecipitation to interrogate CUL3/KLHL7 interactions. For further information and technical support, contact Ascent Research.
